ReviewFrontiers in oncology2026
A glimpse into the CyberKnife robotic radiosurgery system: technical specifications and developments during thirty years.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The CyberKnife system is a state-of-the-art technology widely used in the treatment of cancer. It incorporates a 6 MV X-band linear accelerator mounted on a six-degree-of-freedom (6DOF) robotic arm, combined with an image-guidance platform, to deliver high-dose stereotactic body radiation from a variety of unique angles with sub-millimeter accuracy to the targets in the body. As a frameless and semi-automated treatment, CyberKnife also enables patients to breathe normally during treatment while the robotic arm dynamically tracks and corrects their motion. This review aims to provide an overview of the evolution of the CyberKnife system from its introduction in 1994 through 2026, summarize target-tracking strategies, assess accuracy in both static and moving targets, and highlight its clinical applications, including re-irradiation settings, dose prescriptions and survival outcomes. Additionally, the advantages, challenges, and recent advances of the CyberKnife system are discussed to provide a comprehensive perspective on its role in modern radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.